Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate

Tier C — Watch / trade

Dongwha Pharmaceutical Co., Ltd.

Originator

2023

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：SGLT2, DPP4

Brand：Sidapvia

Indications (approved)：Type 2 diabetes

Regional status

Phase I

2022-03-04

China

Japan

Factories producing this API13

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

13 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate?

Approved indications include: Type 2 diabetes.

When does the Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate patent expire?

No public expiry year is available for Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate yet; this page updates once verified.

How do I get a quote for Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27